Reference
Rauf MS, et al. Brentuximab vedotin for relapsed or refractory Hodgkin Lymphoma, Single center experience King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia. Bone Marrow Transplantation 52 (Suppl. 1): 331-332 (plus poster) abstr. B296, 2017 [abstract] - SaudiArabia
Rights and permissions
About this article
Cite this article
Brentuximab-vedotin. Reactions Weekly 1696, 69 (2018). https://doi.org/10.1007/s40278-018-44257-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-44257-8